2025 Activate Fellow

FOR IMMEDIATE RELEASE

June 11, 2025

Ann Arbor, MI —

We’re proud to announce that Intero Biosystems’ CEO and co-founder, Charlie Childs Ph.D., has been selected as a member of the Activate Fellowship’s 2025 cohort.

Activate is a premier fellowship program that empowers scientists and engineers to transform their research into world-changing startups. Fellows receive two years of funding, mentorship, and intensive entrepreneurial support through a national network of leaders in science, technology, and business.

As part of this highly competitive program, Charlie will have the opportunity to accelerate Intero’s mission: building human-relevant, stem cell–derived organoid models that reduce reliance on animal testing and bring safer, more effective drugs to patients faster.

We’re honored to be part of a community that includes some of the most innovative minds in deep tech—and we’re excited for what’s ahead!

To read more about the fellowship here, CLICK HERE.

 . . .

ABOUT INTERO BIOSYSTEMS
Intero Biosystems is a biotechnology company developing advanced adult human stem cell–derived intestinal organoid platforms for drug discovery and development. Founded in 2024 as a spin-out from Dr. Jason Spence’s lab at the University of Michigan, Intero’s mission is to improve the predictability and efficiency of preclinical testing—failing ineffective drug candidates faster and helping identify safer, more effective treatments for patients in need.

MEDIA CONTACT
Charlie Childs, Ph.D.
CEO, Intero Biosystems
charlie@interobiosystems.com
www.interobiosystems.com